Mirum Pharmaceuticals, Inc. (MIRM) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1249012,
    "name": "Mirum Pharmaceuticals, Inc.",
    "stock_name": "Mirum Pharmaceuticals, Inc.",
    "full_name": "Mirum Pharmaceuticals, Inc.",
    "name_url": "stocks-analysis/mirum-pharmaceuticals-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "71.53",
    "chg": 1.65,
    "chgp": "2.36%",
    "dir": 1,
    "prev_price": "69.88",
    "mcapval": "3,887.89",
    "mcap": "Small Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US6047491013",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "468.33 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/mirum-pharmaceuticals-inc-1249012-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Mirum Pharmaceuticals Experiences Revision in Stock Evaluation Amid Strong Market Performance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/mirum-pharmaceuticals-technical-trend-changes-from-bullish-to-mildly-bullish-amid-stock-price-increase-3649042",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/MirumPharmaceut_technicaldot_3649042.png",
        "date": "2025-10-27 15:50:24",
        "description": "Mirum Pharmaceuticals, Inc. has shown notable resilience in the Pharmaceuticals & Biotechnology sector, achieving a 77.90% return over the past year, significantly outperforming the S&P 500. The company's mixed technical indicators reflect varying trends, while its three-year performance highlights a remarkable recovery compared to broader market benchmarks."
      },
      {
        "title": "Is Mirum Pharmaceuticals, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-mirum-pharmaceuticals-inc-technically-bullish-or-bearish-3547975",
        "imagepath": "",
        "date": "2025-09-20 20:07:07",
        "description": "As of 18 June 2025, the technical trend for Mirum Pharmaceuticals, Inc. has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The MACD is bullish on both weekly and monthly time frames, and moving averages are bullish on the daily time frame. Additionally, Bollinger Bands, KST, Dow Theory, and OBV all indicate bullish trends on both weekly and monthly periods. However, the RSI shows bearish signals on both weekly and monthly time frames, suggesting some caution.\n\nIn terms of performance, Mirum Pharmaceuticals has significantly outperformed the S&P 500 over various periods, with a year-to-date return of 82.15% compared to the S&P 500's 12.22%, and a 1-year return of 98.73% versus 17.14%. Overall, the technical indicators suggest a strong bullish stance despite some mixed signals from the RSI...."
      },
      {
        "title": "Is Mirum Pharmaceuticals, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-mirum-pharmaceuticals-inc-overvalued-or-undervalued-3544171",
        "imagepath": "",
        "date": "2025-09-20 18:39:43",
        "description": "As of 5 August 2021, the valuation grade for Mirum Pharmaceuticals, Inc. moved from does not qualify to risky. Based on the available metrics, the company appears to be overvalued. Key ratios include a Price to Book Value of 9.85, an EV to Sales ratio of 6.14, and a ROE of -33.16%. In comparison to peers, TG Therapeutics, Inc. has a P/E of 83.91, while Catalyst Pharmaceuticals, Inc. shows a much more attractive P/E of 12.14, highlighting the relative overvaluation of Mirum.\n\nDespite the overvaluation, Mirum has shown strong stock performance, with a year-to-date return of 82.15%, significantly outperforming the S&P 500's 12.22% return in the same period. However, the negative profitability metrics and high valuation ratios suggest caution for potential investors...."
      }
    ],
    "total": 9,
    "sid": "1249012",
    "stock_news_url": "https://www.marketsmojo.com/news/mirum-pharmaceuticals-inc-1249012"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Mirum Pharmaceuticals Experiences Revision in Stock Evaluation Amid Strong Market Performance

2025-10-27 15:50:24

Mirum Pharmaceuticals, Inc. has shown notable resilience in the Pharmaceuticals & Biotechnology sector, achieving a 77.90% return over the past year, significantly outperforming the S&P 500. The company's mixed technical indicators reflect varying trends, while its three-year performance highlights a remarkable recovery compared to broader market benchmarks.

Is Mirum Pharmaceuticals, Inc. technically bullish or bearish?

2025-09-20 20:07:07

As of 18 June 2025, the technical trend for Mirum Pharmaceuticals, Inc. has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The MACD is bullish on both weekly and monthly time frames, and moving averages are bullish on the daily time frame. Additionally, Bollinger Bands, KST, Dow Theory, and OBV all indicate bullish trends on both weekly and monthly periods. However, the RSI shows bearish signals on both weekly and monthly time frames, suggesting some caution. In terms of performance, Mirum Pharmaceuticals has significantly outperformed the S&P 500 over various periods, with a year-to-date return of 82.15% compared to the S&P 500's 12.22%, and a 1-year return of 98.73% versus 17.14%. Overall, the technical indicators suggest a strong bullish stance despite some mixed signals from the RSI....

Is Mirum Pharmaceuticals, Inc. overvalued or undervalued?

2025-09-20 18:39:43

As of 5 August 2021, the valuation grade for Mirum Pharmaceuticals, Inc. moved from does not qualify to risky. Based on the available metrics, the company appears to be overvalued. Key ratios include a Price to Book Value of 9.85, an EV to Sales ratio of 6.14, and a ROE of -33.16%. In comparison to peers, TG Therapeutics, Inc. has a P/E of 83.91, while Catalyst Pharmaceuticals, Inc. shows a much more attractive P/E of 12.14, highlighting the relative overvaluation of Mirum. Despite the overvaluation, Mirum has shown strong stock performance, with a year-to-date return of 82.15%, significantly outperforming the S&P 500's 12.22% return in the same period. However, the negative profitability metrics and high valuation ratios suggest caution for potential investors....

View All News